araag2/HINT huggingface dataset:
Clinical trial NCT00628043 (phase 3, status: completed)
Conditions: anemia
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: epoetin beta, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Lung cancer or gynecologic cancer patients

          -  Undergoing platinum-based chemotherapy repeated for ≧ 2 cycles after erythropoietin
             (EPO) or placebo administration

          -  8.0 g/dL ≦ hemoglobin concentration (Hb) ≦ 10.0 g/dL

          -  20 - 79 years old

          -  Performance status: 0 - 2

          -  No iron deficiency anemia

        Exclusion Criteria:

          -  Red blood cell transfusion within 4 weeks before treatment

          -  Erythropoietin therapy within 8 weeks before treatment
Clinical trial NCT00415519 (phase 3, status: completed)
Conditions: amyotrophic lateral sclerosis (als)
ICD codes: G12.21
Drugs: mci-186, placebo of mci-186
SMILES: CC1=NN(C(=O)C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients who are defined as "definite ALS," "probable ALS" or
             "probable-laboratory-supported ALS," met diagnostic criteria revised EL Escorial for
             Airlie House.

          -  Patients who cannot take at least one action of eating a meal, excreting, or moving
             with oneself alone, and need assistance in everyday life.

          -  Patients whose progress of the condition during 12 weeks before administration meet
             other requirements.

        Exclusion Criteria:

          -  Patients judged to be inadequate to participate in this study by their physician,
             because those patients' general condition deteriorated to the point that they need to
             be hospitalized for severe hepatic disease, sever heart disease, sever renal disease
             and so on, or they need to be administered antibiotics to infection.

          -  Patients who complain the difficulty in breathing caused by deteriorating the
             respiratory function.

          -  Patients with such complications as Parkinson's disease, schizophrenia, dementia,
             renal failure, or other severe complication, and patients who have the anamnesis of
             hypersensitivity to edaravone.

          -  Pregnant, lactating, and probably pregnant patients, and patients who want to become
             pregnant, and patients who can not agree to contraception.

          -  Patients who have been administered other investigational products within 12 weeks
             before consent, or who are participating in other clinical trials at present.

          -  In addition to the above exclusion criteria, patients judged to be inadequate to
             participate in this study by their physician.
Clinical trial NCT00720265 (phase 3, status: completed)
Conditions: kidney transplantation
ICD codes: N26.2, Q63.0, Q63.2, Z52.4, I75.81, N19, N20.0
Drugs: prograf, mr4
SMILES: CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Patient must receive first oral dose of randomized study drug 2days(min 1day) prior to
             transplant procedure

          -  Female patients of child bearing potential must have a negative urine or serum
             pregnancy test within 7 days prior to enrollment

        Exclusion Criteria:

          -  Patient has previously received an organ transplant other than a kidney

          -  Patient has received a Kidney transplant from non-heart beating donor or a cadaveric
             donor

          -  Patients has received an ABO incompatible donor kidney

          -  Recipient or donor is known to be seropositive for human immunodeficiency virus(HIV)

          -  Patient has a current malignancy or a history of malignancy (within the past 5 years),
             except non-metastatic basal or squamous cell carcinoma of the skin that has been
             treated successfully

          -  Patient has significant liver, disease, defined as having during the past 28 days
             continuously elevated AST (SGOT) and/or ALT (SGPT) levels greater than 3 times the
             upper value of the normal range of the investigational site

          -  Patient has an uncontrolled concomitant infection(including Hepatitis B, Hepatitis
             C)or any other unstable medical condition that could interfere with the study
             objectives

          -  Patient is currently taking or has been taking an immunosuppressive agents in the 30
             days prior to transplant(except from two days prior to transplant)

          -  Patient has a known hypersensitivity to tacrolimus

          -  Patient is pregnant or lactating
Clinical trial NCT00406367 (phase 3, status: completed)
Conditions: blepharospasm
ICD codes: G24.5
Drugs: incobotulinumtoxina (xeomin), placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Main Inclusion Criteria:

          -  Male or female pretreated outpatients between ages 18 and 80 years (inclusive)

          -  A clinical diagnosis of bilateral blepharospasm (BEB) characterized by spontaneous,
             spasmodic, intermittent or persistent involuntary contractions of the orbicular oculi
             muscles

          -  A need for injection of Botulinum toxin (defined by a Jankovic Rating Scale (JRS)
             severity subscore >= 2)

          -  On a stable dose of other medications (if any) used for focal dystonia treatment (e.g.
             anticholinergics and benzodiazepines) for at least 3 months prior to and expected
             throughout the Main Period

          -  Source documentation of the last two consecutive injection sessions with BOTOX® and a
             stable satisfactory therapeutic response directly prior to trial entry

          -  At least 10 weeks must have been passed between the last injection with BOTOX® for BEB
             and Baseline

        Main Exclusion Criteria:

          -  Atypical variant of BEB caused by inhibition of levator palpebrae muscle

          -  Myotomy or denervation surgery in the affected muscles (e.g. peripheral denervation
             and/or spinal cord stimulation)

          -  The previous two injections with BOTOX® with more than 50 Units per eye

          -  Hypersensitivity to human serum albumin, sucrose, or Botulinum toxin A

          -  Neuroleptic induced blepharospasm

          -  Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis,
             or any other significant neuromuscular disease which might interfere with the trial

          -  Treatment with Botulinum toxins for any indication other than BEB within 4 months
             prior to Baseline and during the trial
Clinical trial NCT01644474 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: alirocumab, ezetimibe, placebo (for alirocumab), placebo (for ezetimibe)
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion criteria:

          -  Participants with hypercholesterolemia

        Exclusion criteria:

          -  Age < 18 or legal age of adulthood, whichever was greater

          -  LDL-C < 100 mg/dL (< 2.59 mmol/L) or > 190 mg/dL (> 4.9 mmol/L)

          -  Fasting serum triglycerides (TG) > 400 mg/dL (> 4.52 mmol/L)

          -  Known history of homozygous or heterozygous familial hypercholesterolemia

        The above information was not intended to contain all considerations relevant to a
        participant's potential participation in a clinical trial.
Clinical trial NCT01172145 (phase 3, status: completed)
Conditions: apathy, alzheimer's disease
ICD codes: R45.3, G30.8, G30.9, G30.0, G30.1
Drugs: modafinil, placebo
SMILES: NC(=O)C[S@@](=O)C(C1=CC=CC=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  diagnosis of mild to moderate stage Probable Alzheimer's disease

          -  on a stable dose of a cholinesterase inhibitor medication for at least 30 days

          -  clinically elevated levels of apathy as measured by the Frontal Systems Behavior Scale

        Exclusion Criteria:

          -  diagnosis of Major Depression

          -  focal brain lesion on neuroimaging

          -  history of significant substance abuse

          -  history of significant head trauma with loss if consciousness >10 minutes
Clinical trial NCT00653952 (phase 3, status: terminated)
Conditions: ovarian neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: caelyx, paclitaxel hcl
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Reason stopped: 
    poor accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven (i.e., not borderline) epithelial ovarian carcinoma

          -  Measurable disease

          -  Recurrence of disease or disease progression indicative of failure of first-line
             platinum-based chemotherapy

          -  Disease-free from prior malignancies for >5 years with the exception of curatively
             treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the
             cervix

          -  Adequate renal creatinine (<2.5 mg/dL (<220 μmol/L)) & liver function (aspartate amino
             transferase (AST) and alanine amino transferase (ALT) <2 x upper limit of normal,
             alkaline phosphatase <2.0 x upper limit of normal, except if attributed to tumor, and
             bilirubin < upper limit of normal)

        Exclusion Criteria:

          -  Pregnant or breast feeding

          -  Life expectancy of <3 months

          -  Prior radiation therapy to more than one-third of hematopoietic sites within 30 days
             prior to first dose of study drug

          -  Prior therapy with DOXIL or paclitaxel

          -  Prior chemotherapy within 28 days of first dose of study drug (or 42 days if subject
             has received a nitrosourea or mitomycin)

          -  Treated with high dose therapy supported by bone marrow or peripheral stem cell
             transplantation at any time
Clinical trial NCT00372567 (phase 3, status: terminated)
Conditions: gastrointestinal stromal tumor
ICD codes: C49.A0, C49.A1, C49.A2, C49.A5, C49.A3, C49.A4, C49.A9
Drugs: sunitinib malate, imatinib mesylate
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C, CN1CCN(CC2=CC=C(C=C2)C(=O)NC2=CC(NC3=NC=CC(=N3)C3=CN=CC=C3)=C(C)C=C2)CC1
Reason stopped: 
    see termination reason in detailed description.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with gastrointestinal stromal tumors whose disease has progressed on imatinib
             400 mg daily.

        Exclusion Criteria:

          -  Current treatment with any chemotherapy other than imatinib.

          -  Current treatment with any dose of imatinib other than 400 mg
Clinical trial NCT00091715 (phase 3, status: completed)
Conditions: pulmonary hypertension
ICD codes: I27.0, I27.20, I27.21, I27.24, I27.29, P29.30, I27.22
Drugs: bosentan, placebo
SMILES: COC1=CC=CC=C1OC1=C(NS(=O)(=O)C2=CC=C(C=C2)C(C)(C)C)N=C(N=C1OCCO)C1=NC=CC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  PAH NYHA Class II

          -  Significant elevation of mean pulmonary arterial pressure

          -  Significant elevation of pulmonary vascular resistance at rest

          -  Limited 6-minute walk distance

        Exclusion Criteria:

          -  PAH secondary to portal hypertension, complex congenital heart disease or reverse
             shunt

          -  Restrictive or obstructive lung disease

          -  Significant vasoreactivity

          -  Treatments for PAH (within 4 weeks of randomization)
Clinical trial NCT00652483 (phase 3, status: completed)
Conditions: glaucoma, ocular hypertension
ICD codes: H40.9, Q15.0, B73.02, H40.823, H40.89, H44.513, H40.821, H40.053, H40.051, H40.052, H40.059
Drugs: brimonidine ophthalmic solution 0.1%, brimonidine ophthalmic solution 0.2%
SMILES: BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12, BrC1=C(NC2=NCCN2)C=CC2=NC=CN=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Ocular hypertension or glaucoma in both eyes

        Exclusion Criteria:

          -  Uncontrolled systemic disease

          -  Known allergy or sensitivity to brimonidine
Clinical trial NCT00464269 (phase 3, status: completed)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: brivaracetam 2.5 mg, brivaracetam 10 mg, brivaracetam 25 mg
SMILES: CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects were 16 to 70 years, both inclusive. Subjects under 18 years of age were only
             included where legally permitted and ethically accepted

          -  Subjects with well-characterized focal epilepsy or epileptic syndrome according to the
             International League Against Epilepsy (ILAE) classification

          -  Subjects had a history of partial onset seizures (POS) whether or not secondarily
             generalized (Type I seizures according to the ILAE classification)

          -  Subjects had at least 2 POS whether or not secondarily generalized per month during
             the 3 months preceding Visit 1 (V1)

          -  Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week
             Baseline Period

          -  Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic
             drug(s) (AEDs). Vagal nerve stimulation (VNS) was allowed and was not counted as a
             concomitant AED

        Exclusion Criteria:

          -  History or presence of seizures occurring only in clusters (too frequently or
             indistinctly separated to be reliably counted) before Visit 3

          -  History or presence of status epilepticus during the year preceding Visit 1 or during
             Baseline
Clinical trial NCT00333034 (phase 3, status: completed)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: etanercept
SMILES: [O-][N+](=O)OC[C@@H](O[N+]([O-])=O)[C@H](CO[N+]([O-])=O)O[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria: -Adults greater than or equal to 18 years of age with clinically stable
        plaque psoriasis involving greater than or equal to 10% of the body surface and a minimum
        Psoriasis Area and Severity Index (PASI) score of 10 at screening. -Failure to respond to,
        or have a contraindication to, or intolerant to at least 1 of the following systemic or
        phototherapies at an adequate dose of sufficient duration: Methotrexate (MTX), Acitretin,
        Cyclosporine, Ultraviolet A (UVA), Ultraviolet B (UVB), Psoralen and Ultraviolet A (PUVA),
        Fumarate Exclusion Criteria: -Previous treatment with etanercept, antibody to TNF or other
        TNF inhibitors. -Active guttate, erythrodermic, or pustular psoriasis at the time of the
        screening or baseline.&#xd;
Clinical trial NCT00465088 (phase 3, status: completed)
Conditions: hyperlipidemia, mixed dyslipidemia
ICD codes: E78.2, E78.49, E78.5
Drugs: niacin er/simvastatin tablets, atorvastatin
SMILES: OC(=O)C1=CN=CC=C1, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must meet all of the following laboratory criteria:

               -  HDL-C <40 mg/dL for men and <50 mg/dL for women.

               -  LDL-C ≥130 mg/dL but <250 mg/dL.

               -  TG <350 mg/dL.

               -  Creatine phosphokinase (CPK) < 3 x upper limit of normal (ULN).

               -  Alanine aminotransferase (ALT); serum glutamic pyruvic transaminase [SGPT] and
                  aspartate aminotransferase (AST); serum glutamic oxaloacetic transaminase [SGOT]
                  < 1.3 x ULN.

          -  Subjects must also be reasonably compliant with the Therapeutic Lifestyle Changes
             (TLC) diet during the 4 to 5 week Screening Period prior to randomization (and be
             willing to comply for the duration of the study).

        Exclusion Criteria:

          -  Subjects who have a history of any important medical conditions or abnormalities (as
             specified in the protocol) that would preclude study inclusion
Clinical trial NCT00300196 (phase 3, status: terminated)
Conditions: stroke, cerebral ischemia, brain infarction
ICD codes: G46.4, G46.3, Z82.3, P91.821, P91.822
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    futility
  
Eligibility criteria:

        Inclusion Criteria:

          -  Acute, ischemic stroke with first symptoms within 6 hours of beginning treatment

          -  Baseline NIHSS > 5

        Exclusion Criteria:

          -  No intracranial, extravascular blood on CT

          -  Hypertension (systolic > 185; diastolic > 105)

          -  Baseline fibrinogen level < 100 mg/dL

          -  Thrombocytopenia (< 100,000 / mm3)

          -  Recent (< 3 days) or anticipated (< 5 days) use of a thrombolytic agent

          -  Recent (< 14 days) or anticipated surgery
Clinical trial NCT00560924 (phase 3, status: terminated)
Conditions: menopause, urinary infections
ICD codes: E28.310, E28.319
Drugs: estradiol, 25 mcg
SMILES: [H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3
Reason stopped: 
    trial prematurely discontinued due to slow recruitment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Post-menopausal woman with Urogenital ageing (UGA)

          -  Recurrent urinary tract infections defined as three or more urinary tract infections
             within the past twelve months

        Exclusion Criteria:

          -  Known or suspected allergy to trial product or related products

          -  Present UTI

          -  History of RUTI during fertile period of life
Clinical trial NCT00476996 (phase 3, status: terminated)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: leflunomide, methotrexate, ocrelizumab, ocrelizumab, placebo
SMILES: CC1=C(C=NO1)C(=O)NC1=CC=C(C=C1)C(F)(F)F, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    recruitment was fully completed for this study; however, the study was terminated during
    conduct after the primary endpoint analysis was completed.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients, ≥ 18 years of age

          -  Rheumatoid arthritis for at least 3 months

          -  Inadequate response to previous or current treatment with at least one anti-TNF-alpha
             agent

          -  Receiving either leflunomide or methotrexate for ≥ 12 weeks, with a stable dose for
             the last 4 weeks

          -  Swollen joint count (SJC) ≥ 4 (66 joint count) and tender joint count (TJC) ≥ 4 (68
             joint count) at screening and baseline.

          -  CRP ≥ 0.6 mg/dL using a high-sensitivity assay.

          -  Positive rheumatoid factor or positive anti-CCP antibody or both.

        Exclusion Criteria:

          -  Rheumatic autoimmune disease or inflammatory joint disease, other than RA

          -  Any surgical procedure in past 12 weeks,or planned within 48 weeks of baseline
Clinical trial NCT00397033 (phase 3, status: completed)
Conditions: schizoaffective disorder, psychotic disorder
ICD codes: F25.9, F25.0, F25.1, F25.8, F23, F24, F12.159, F12.259, F12.150, F12.151, F12.250
Drugs: paliperidone er, paliperidone er, placebo
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnostic and Statistical Manual - Fourth Edition (DSM-IV) diagnosis of
             schizoaffective disorder

          -  A total Positive and Negative Symptoms of Schizophrenia (PANSS) score of >= 60

          -  A score of >= 16 on Young Mania Rating Scale (YMRS) or a score of >= 16 on the
             Hamilton Depression Rating Scale (HAM-D 21)

        Exclusion Criteria:

          -  A primary active mental illness diagnosis other than schizoaffective disorder

          -  Patients with first episode psychosis

          -  Active substance dependence within previous 6 months

          -  Treatment with clozapine within 6 months of randomization

          -  A history of treatment resistance, defined by failure to respond to 2 adequate trials
             of antipsychotic medication

          -  Pregnancy, breast-feeding, or planning to become pregnant
Clinical trial NCT00156117 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: asenapine, placebo, olanzapine
SMILES: OC(=O)\C=C/C(O)=O.CN1CC2C(C1)C1=C(OC3=CC=CC=C23)C=CC(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Currently suffering from an acute exacerbation of schizophrenia. Caregiver required.

        Exclusion Criteria:

          -  Have an uncontrolled, unstable medical condition. Have any other psychiatric disorder
             other than schizophrenia as a primary diagnosis.
Clinical trial NCT00034944 (phase 3, status: completed)
Conditions: major depressive disorder
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40
Drugs: mk0869, aprepitant, comparator: placebo
SMILES: C[C@@H](O[C@H]1OCCN(CC2=NNC(=O)N2)[C@H]1C1=CC=C(F)C=C1)C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F, CN(C)C(=N)NC(N)=N
Eligibility criteria:

        Major depressive disorder
Clinical trial NCT01126541 (phase 3, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: rituximab
SMILES: ClCCN(CCCl)P1(=O)NCCCO1
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients >18 years of age

          -  RA for >=6 months

          -  Receiving outpatient treatment

          -  Ongoing treatment with methotrexate for >=3 months, stable for >=1 month

          -  Inadequate response or intolerance to etanercept, infliximab or adalimumab

        Exclusion Criteria:

          -  Previous treatment with MabThera

          -  Concurrent treatment with any anti TNF-alfa therapy or biologic therapy

          -  Previous treatment with any investigational cell-depleting therapies